By Application
Hot products 
-
Mouse Anti-BPGM Recombinant Antibody (CBYY-1806) (CBMAB-2155-YY)
-
Mouse Anti-C4B Recombinant Antibody (CBYY-C2996) (CBMAB-C4439-YY)
-
Mouse Anti-AFM Recombinant Antibody (V2-634159) (CBMAB-AP185LY)
-
Mouse Anti-2C TCR Recombinant Antibody (V2-1556) (CBMAB-0951-LY)
-
Mouse Anti-CSPG4 Recombinant Antibody (CBFYM-1050) (CBMAB-M1203-FY)
-
Mouse Anti-AK4 Recombinant Antibody (V2-180419) (CBMAB-A1891-YC)
-
Rabbit Anti-B2M Recombinant Antibody (CBYY-0059) (CBMAB-0059-YY)
-
Mouse Anti-CORO1A Recombinant Antibody (4G10) (V2LY-1206-LY806)
-
Mouse Anti-ARG1 Recombinant Antibody (CBYCL-103) (CBMAB-L0004-YC)
-
Mouse Anti-CD247 Recombinant Antibody (6B10.2) (CBMAB-C1583-YY)
-
Mouse Anti-CASP8 Recombinant Antibody (CBYY-C0987) (CBMAB-C2424-YY)
-
Mouse Anti-CDK7 Recombinant Antibody (CBYY-C1783) (CBMAB-C3221-YY)
-
Mouse Anti-ACLY Recombinant Antibody (V2-179314) (CBMAB-A0610-YC)
-
Mouse Anti-BCL6 Recombinant Antibody (CBYY-0442) (CBMAB-0445-YY)
-
Mouse Anti-14-3-3 Pan Recombinant Antibody (V2-9272) (CBMAB-1181-LY)
-
Mouse Anti-CRTAM Recombinant Antibody (CBFYC-2235) (CBMAB-C2305-FY)
-
Mouse Anti-ADV Recombinant Antibody (V2-503423) (CBMAB-V208-1364-FY)
-
Rabbit Anti-ALK (Phosphorylated Y1278) Recombinant Antibody (D59G10) (PTM-CBMAB-0035YC)
-
Mouse Anti-ALB Recombinant Antibody (V2-55272) (CBMAB-H0819-FY)
-
Rat Anti-ABCC11 Recombinant Antibody (V2-179001) (CBMAB-A0236-YC)
Prostate Cancer
Fig.1 Prostate cancer
Prostate cancer is regarded as glandular cancer or adenocarcinoma, which starts when normal semen-secreting prostate gland cells mutation happens and changes into cancer cells. The majority of prostate cancers are slow-growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other sites of the body, particularly the lymph nodes and bones. It may initially cause no symptoms. But in later stages it can lead to difficulty urinating, blood in the urine, pain in the pelvis when urinating. The primary risk factors are age, obesity, and family history. Around 99% of cases occur in people over the age of 50 and the average age at the time of diagnosis is around 70. Mutations in BRCA1 and BRCA2 are important risk factors for ovarian cancer and breast cancer in women, have also been implicated in prostate cancer. The expression of Ki-67 by immunohistochemistry may be a significant predictor of patient outcome for men with prostate cancer.
Loading...
Compare
